|
|
Blood, 15 December 2005, Vol. 106, No. 13, pp. 4330-4338.
Prepublished online as a Blood First Edition Paper on August 25, 2005; DOI 10.1182/blood-2005-07-2819.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non–COX-2 inhibitory analog of celecoxib
Adel Kardosh,
Nathaniel Soriano,
Yen-Ting Liu,
Jasim Uddin,
Nicos A. Petasis,
Florence M. Hofman,
Thomas C. Chen, and
Axel H. Schönthal
From the Departments of Molecular Microbiology and Immunology, Pathology, Chemistry, and Neurosurgery, University of Southern California, Los Angeles, CA.
2,5-dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib that lacks COX-2 inhibitory function. We and others have demonstrated that DMC, despite its inability to block COX-2, is able to potently mimic the antitumor effects of celecoxib in vitro and in vivo. In this current study, we investigated whether DMC would also be able to inhibit the growth of highly drug-resistant tumor cell variants. We focused on human multiple myeloma (MM) cells, as patients with MM frequently develop drug-resistant disease and ultimately succumb to death. Here we show that DMC (and celecoxib) inhibits the proliferation of various multiple myeloma cell lines, including several (multi) drug-resistant variants. Growth inhibition in drug-sensitive and drug-resistant cells is mediated via multiple effects, which include diminished signal transducer and activator of transcription 3 (STAT-3) and mitogen-activated protein (MAP) kinase kinase (MEK) activity, reduced expression of survivin and various cyclins, and is followed by apoptotic cell death. Thus, our study demonstrates that inhibition of proliferation and induction of apoptosis by DMC (and celecoxib) can be accomplished even in highly drug-resistant multiple myeloma cells, and that this effect is achieved via the blockage of multiple targets that are critical for multiple myeloma cell growth and survival.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Not all that glitters is gold
- Yair Gazitt
Blood 2005 106: 4025-4026.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
E. B. Golden, P. Y. Lam, A. Kardosh, K. J. Gaffney, E. Cadenas, S. G. Louie, N. A. Petasis, T. C. Chen, and A. H. Schonthal
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors
Blood,
June 4, 2009;
113(23):
5927 - 5937.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kardosh, E. B. Golden, P. Pyrko, J. Uddin, F. M. Hofman, T. C. Chen, S. G. Louie, N. A. Petasis, and A. H. Schonthal
Aggravated Endoplasmic Reticulum Stress as a Basis for Enhanced Glioblastoma Cell Killing by Bortezomib in Combination with Celecoxib or Its Non-Coxib Analogue, 2,5-Dimethyl-Celecoxib
Cancer Res.,
February 1, 2008;
68(3):
843 - 851.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Wang, X. Y. Yang, X. Zhang, and W. L. Farrar
Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPAR{gamma} cross talk with NF-{kappa}B and C/EBP
Blood,
December 15, 2007;
110(13):
4373 - 4384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Pyrko, A. Kardosh, W. Wang, W. Xiong, A. H. Schonthal, and T. C. Chen
HIV-1 Protease Inhibitors Nelfinavir and Atazanavir Induce Malignant Glioma Death by Triggering Endoplasmic Reticulum Stress
Cancer Res.,
November 15, 2007;
67(22):
10920 - 10928.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Zhang, A. Suvannasankha, C. D. Crean, V. L. White, A. Johnson, C.-S. Chen, and S. S. Farag
OSU-03012, a Novel Celecoxib Derivative, Is Cytotoxic to Myeloma Cells and Acts through Multiple Mechanisms
Clin. Cancer Res.,
August 15, 2007;
13(16):
4750 - 4758.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Pyrko, A. Kardosh, Y.-T. Liu, N. Soriano, W. Xiong, R. H. Chow, J. Uddin, N. A. Petasis, A. K. Mircheff, R. A. Farley, et al.
Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib
Mol. Cancer Ther.,
April 1, 2007;
6(4):
1262 - 1275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lou, N. Fatima, Z. Xiao, S. Stauffer, G. Smythers, P. Greenwald, and I. U. Ali
Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells.
Cancer Epidemiol. Biomarkers Prev.,
September 1, 2006;
15(9):
1598 - 1606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Hoang, L. Zhu, Y. Shi, P. Frost, H. Yan, S. Sharma, S. Sharma, L. Goodglick, S. Dubinett, and A. Lichtenstein
Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance
Blood,
June 1, 2006;
107(11):
4484 - 4490.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
